Our previous works demonstrated the role of tumor suppressor for PTPRG in CML [12] and, in a different cell context, its capability to target JAK2 [30], a kinase governing pathways of relevant therapeutic interest in CML [31]. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.